(Q43810735)

27 November 2017

title

Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation (English)

1 reference

27 November 2017

1 reference

Mofsen R

1

1 reference

27 November 2017

Balter J

series ordinal

2

1 reference

27 November 2017

publication date

1 October 2001

1 reference

27 November 2017

published in

Clinical Therapeutics

1 reference

27 November 2017

volume

23

1 reference

27 November 2017

issue

10

1 reference

27 November 2017

page(s)

1720-1731

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980139-9

7 January 2021

No D2 receptor increase in PET study of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980139-9

7 January 2021

Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980139-9

7 January 2021

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980139-9

7 January 2021

Clozapine in the back wards

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980139-9

7 January 2021

10.1016/S0149-2918(01)80139-9

Identifiers

DOI

1 reference

27 November 2017

1 reference